H.C. Wainwright does not see direct read from Roche miss to Olema’s OPERA-02

3 weeks ago 17

Skip to navigation Skip to main contented Skip to close file

TipRanks

Tue, March 10, 2026 astatine 10:20 AM CDT 1 min read

H.C. Wainwright notes that Roche’s (RHHBY) persevERA proceedings “disappointingly” failed, though the steadfast does not presumption the frontline accidental arsenic eliminated for palazestrant and does not judge the persevERA proceedings is “a implicit readthrough” to Olema Oncology’s (OLMA) OPERA-02 trial, which is evaluating palazestrant positive ribociclib. Differences successful combo agents could favour OPERA-02, argues the analyst, who keeps a Buy standing connected Olema shares.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected OLMA:

Disclaimer & DisclosureReport an Issue

Olema Pharmaceuticals, Inc. (OLMA) Q4 Earnings Cheat Sheet
Asymmetric Upside connected Olema Ahead of Roche’s persevERA Readout: Buy/High Risk Maintained connected Palazestrant Optionality
Olema Oncology initiated with a Buy astatine Stifel
Olema Pharmaceuticals CFO Departs; CEO Assumes Interim Role
Olema Oncology announces departure of COO, CFO Shane Kovacs

Read Entire Article